恩格列净降低合并及不合并糖尿病个体的肝脏脂肪
研究将30例2型糖尿病和27例非糖尿病患者随机双盲接受恩格列净或安慰剂(2:1)治疗12周。恩格列净组肝脏脂肪含量绝对降低2.39%±0.79%,安慰剂组增加0.91%±0.64%(P<0.007)。肝脏脂肪降低与基线肝脂肪含量、体重下降和胰岛素敏感性改善强相关,与血糖或HbA1c下降无关。
要点
- 恩格列净治疗12周降低肝脏脂肪含量,降幅与是否合并2型糖尿病无关。
- 肝脏脂肪降低与体重下降和胰岛素敏感性改善强相关,与血糖下降无关。
- 恩格列净组肝脏脂肪绝对降低2.39%±0.79%,安慰剂组增加0.91%±0.64%。
核心结论
- 恩格列净能有效降低合并和不合并2型糖尿病个体的肝脏脂肪含量。
- 肝脏脂肪含量的降低独立于血浆葡萄糖浓度的下降,与体重下降和胰岛素敏感性改善强相关。
研究设计与样本
- 30例2型糖尿病患者和27例非糖尿病患者随机双盲接受恩格列净或匹配安慰剂(2:1比例)治疗12周。
- 治疗前后进行75g口服葡萄糖耐量试验,并用磁共振波谱(MRS)测量肝脏脂肪含量。
- 治疗前用3-3H-葡萄糖测量肝葡萄糖生成。
主要发现
- 恩格列净组肝脏脂肪含量绝对降低2.39%±0.79%,安慰剂组增加0.91%±0.64%(P<0.007,方差分析)。
- 肝脏脂肪降低在糖尿病患者和非糖尿病患者中相当(分别为2.75%±0.81%和1.93%±0.78%;P=NS)。
- 恩格列净引起的肝脏脂肪降低与基线肝脏脂肪含量强相关(r=-0.62;P<0.001)。
- 肝脏脂肪降低与体重下降(r=0.53;P<0.001)和胰岛素敏感性改善(r=-0.51;P<0.001)强相关。
- 肝脏脂肪降低与空腹血糖或HbA1c下降以及肝葡萄糖生成增加无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the effect of empagliflozin on liver fat content in individuals with and without type 2 diabetes (T2D) and the relationship between the decrease in liver fat and other metabolic actions of empagliflozin. RESEARCH DESIGN AND METHODS: Thirty individuals with T2D and 27 without were randomly assigned to receive in double-blind fashion empagliflozin or matching placebo (2:1 ratio) for 12 weeks. Participants underwent 75-g oral glucose tolerance testing and measurement of liver fat content with MRS before therapy and at study end. Hepatic glucose production before the start of therapy was measured with 3-3H-glucose. RESULTS: Empagliflozin caused an absolute reduction of 2.39% ± 0.79% in liver fat content compared with an increase of 0.91% ± 0.64% in participants receiving placebo (P < 0.007 with ANOVA). The decrease in liver fat was comparable in both individuals with diabetes and those without (2.75% ± 0.81% and 1.93% ± 0.78%, respectively; P = NS). The decrease in hepatic fat content caused by empagliflozin was strongly correlated with baseline liver fat content (r = -0.62; P < 0.001), decrease in body weight (r = 0.53; P < 0.001), and improvement in insulin sensitivity (r = -0.51; P < 0.001) but was not related to the decrease in fasting plasma glucose or HbA1c or the increase in hepatic glucose production. CONCLUSIONS: Empagliflozin is effective in reducing liver fat content in individuals with and without T2D. The decrease in liver fat content is independent of the decrease in plasma glucose concentration and is strongly related to the decrease in body weight and improvement in insulin sensitivity.
引用
- Abdelgani S, Khattab A, Adams J, et al. Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes Care. 2024. PMID: 38295394. doi:10.2337/dc23-1646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。